TW202402276A - 新穎吲唑衍生物 - Google Patents
新穎吲唑衍生物 Download PDFInfo
- Publication number
- TW202402276A TW202402276A TW112117717A TW112117717A TW202402276A TW 202402276 A TW202402276 A TW 202402276A TW 112117717 A TW112117717 A TW 112117717A TW 112117717 A TW112117717 A TW 112117717A TW 202402276 A TW202402276 A TW 202402276A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- methyl
- formula
- mmol
- indazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22173211.8 | 2022-05-13 | ||
| EP22173211 | 2022-05-13 | ||
| EP22175324 | 2022-05-25 | ||
| EP22175324.7 | 2022-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202402276A true TW202402276A (zh) | 2024-01-16 |
Family
ID=86604076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112117717A TW202402276A (zh) | 2022-05-13 | 2023-05-12 | 新穎吲唑衍生物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250313565A1 (enExample) |
| EP (1) | EP4522617A1 (enExample) |
| JP (1) | JP2025515833A (enExample) |
| KR (1) | KR20250012058A (enExample) |
| CN (1) | CN119173518A (enExample) |
| AR (1) | AR129307A1 (enExample) |
| AU (1) | AU2023269227A1 (enExample) |
| CA (1) | CA3256325A1 (enExample) |
| TW (1) | TW202402276A (enExample) |
| WO (1) | WO2023217923A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020254565A1 (en) | 2019-06-21 | 2020-12-24 | F. Hoffmann-La Roche Ag | Egfr inhibitors for the treatment of cancer |
| WO2022117475A1 (en) | 2020-12-01 | 2022-06-09 | F. Hoffmann-La Roche Ag | New indazole derivatives |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020254565A1 (en) * | 2019-06-21 | 2020-12-24 | F. Hoffmann-La Roche Ag | Egfr inhibitors for the treatment of cancer |
-
2023
- 2023-05-11 EP EP23726341.3A patent/EP4522617A1/en active Pending
- 2023-05-11 US US18/865,278 patent/US20250313565A1/en active Pending
- 2023-05-11 AU AU2023269227A patent/AU2023269227A1/en active Pending
- 2023-05-11 JP JP2024566738A patent/JP2025515833A/ja active Pending
- 2023-05-11 CN CN202380039816.2A patent/CN119173518A/zh active Pending
- 2023-05-11 KR KR1020247037659A patent/KR20250012058A/ko active Pending
- 2023-05-11 CA CA3256325A patent/CA3256325A1/en active Pending
- 2023-05-11 WO PCT/EP2023/062529 patent/WO2023217923A1/en not_active Ceased
- 2023-05-12 TW TW112117717A patent/TW202402276A/zh unknown
- 2023-05-12 AR ARP230101177A patent/AR129307A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3256325A1 (en) | 2023-11-16 |
| AU2023269227A1 (en) | 2024-10-03 |
| JP2025515833A (ja) | 2025-05-20 |
| EP4522617A1 (en) | 2025-03-19 |
| AR129307A1 (es) | 2024-08-07 |
| KR20250012058A (ko) | 2025-01-23 |
| WO2023217923A1 (en) | 2023-11-16 |
| CN119173518A (zh) | 2024-12-20 |
| US20250313565A1 (en) | 2025-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7561779B2 (ja) | 新規ｅｇｆｒ阻害剤 | |
| TWI833773B (zh) | 化合物 | |
| EP3986895A1 (en) | Egfr inhibitors for the treatment of cancer | |
| JP7840324B2 (ja) | 新規インダゾール誘導体 | |
| JP7701360B2 (ja) | Ｅｇｆｒ阻害剤 | |
| TWI915460B (zh) | 新穎吲唑乙炔衍生物、製備其之方法、包含其之醫藥組合物及其用途 | |
| JP7798887B2 (ja) | 新規インダゾール誘導体 | |
| WO2023217923A1 (en) | New indazole derivatives | |
| RU2853003C1 (ru) | Новые индазолацетиленовые производные | |
| HK40115444A (zh) | 新的吲唑衍生物 | |
| HK40092553A (zh) | 新的吲唑衍生物 | |
| HK40094041A (zh) | 新的吲唑乙炔衍生物 | |
| HK40067220A (zh) | 新egfr抑制剂 |